163 related articles for article (PubMed ID: 27603506)
1. A Lipophilic Pt(IV) Oxaliplatin Derivative Enhances Antitumor Activity.
Abu Ammar A; Raveendran R; Gibson D; Nassar T; Benita S
J Med Chem; 2016 Oct; 59(19):9035-9046. PubMed ID: 27603506
[TBL] [Abstract][Full Text] [Related]
2. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
4. Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer.
Wu M; Li H; Liu R; Gao X; Zhang M; Liu P; Fu Z; Yang J; Zhang-Negrerie D; Gao Q
Eur J Med Chem; 2016 Mar; 110():32-42. PubMed ID: 26807543
[TBL] [Abstract][Full Text] [Related]
5. Design of a novel theranostic nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene-platinum(II) conjugate.
Avaji PG; Park JH; Lee HJ; Jun YJ; Park KS; Lee KE; Choi SJ; Lee HJ; Sohn YS
Int J Nanomedicine; 2016; 11():837-51. PubMed ID: 27042052
[TBL] [Abstract][Full Text] [Related]
6. Pt(IV) Bifunctional Prodrug Containing 2-(2-Propynyl)octanoato Axial Ligand: Induction of Immunogenic Cell Death on Colon Cancer.
Sabbatini M; Zanellato I; Ravera M; Gabano E; Perin E; Rangone B; Osella D
J Med Chem; 2019 Apr; 62(7):3395-3406. PubMed ID: 30879295
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.
Göschl S; Schreiber-Brynzak E; Pichler V; Cseh K; Heffeter P; Jungwirth U; Jakupec MA; Berger W; Keppler BK
Metallomics; 2017 Mar; 9(3):309-322. PubMed ID: 28205649
[TBL] [Abstract][Full Text] [Related]
9. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
Ravera M; Perin E; Gabano E; Zanellato I; Panzarasa G; Sparnacci K; Laus M; Osella D
J Inorg Biochem; 2015 Oct; 151():132-42. PubMed ID: 26277416
[TBL] [Abstract][Full Text] [Related]
10. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
11. Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs.
Ravera M; Gabano E; Zanellato I; Bonarrigo I; Alessio M; Arnesano F; Galliani A; Natile G; Osella D
J Inorg Biochem; 2015 Sep; 150():1-8. PubMed ID: 26042542
[TBL] [Abstract][Full Text] [Related]
12. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Komeda S; Takayama H; Suzuki T; Odani A; Yamori T; Chikuma M
Metallomics; 2013 May; 5(5):461-8. PubMed ID: 23608770
[TBL] [Abstract][Full Text] [Related]
14. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
16. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.
Shord SS; Bernard SA; Lindley C; Blodgett A; Mehta V; Churchel MA; Poole M; Pescatore SL; Luo FR; Chaney SG
Anticancer Res; 2002; 22(4):2301-9. PubMed ID: 12174918
[TBL] [Abstract][Full Text] [Related]
18. A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin.
Zhang Y; Zhang Q; Fan Z; Sun J; Liu X; Cheng L; Li A; Xu J
Pathol Oncol Res; 2015 Apr; 21(2):389-97. PubMed ID: 25103530
[TBL] [Abstract][Full Text] [Related]
19. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
20. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]